{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:44Z","timestamp":1791355784822,"version":"4.3.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extended-release injectable naltrexone (XR-NTX), a long-acting opioid antagonist, is an effective relapse prevention strategy in the treatment of opioid use disorder (OUD). However, standard XR-NTX initiation requires completion of opioid withdrawal management and a 1\u20132 week opioid-free period. This interval is associated with heightened vulnerability to lapse and relapse, and many patients fail to initiate XR-NTX treatment successfully. Therefore, alternative strategies that enable rapid XR-NTX initiation are needed. This study aimed to compare the effectiveness and safety of naltrexone-accelerated (NA) versus sublingual buprenorphine (SB) withdrawal management in facilitating XR-NTX initiation among patients with OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, open-label, randomized controlled trial uses a parallel-group design. Eligible patients aged 18\u201360 years with moderate to severe OUD who are actively using opioids and are not receiving regular maintenance treatment with methadone or buprenorphine are randomly assigned to one of two groups: (1) NA withdrawal management, comprising one day of adjunctive non-opioid medications, one day of buprenorphine administration, one day of washout, and four days of gradual oral naltrexone titration (1, 3, 12, and 25 mg\/day); or (2) SB withdrawal management, comprising one day of adjunctive non-opioid medications, six days of buprenorphine tapering (up to 8 mg on Day 2, 6 mg on Day 3, 4 mg on Days 4\u20135, 2 mg on Day 6, and 1 mg on Day 7), and a seven-day washout period. Adjunctive non-opioid medications in both groups comprised clonidine, clonazepam, gabapentin, and trazodone. The primary outcomes are the proportions of participants who (1) achieve a negative urine drug test for the assessed opioids and (2) receive XR-NTX at the end of the withdrawal management period. Secondary outcomes include severity of withdrawal symptoms, opioid craving intensity, and adverse effects. All analyses are conducted according to the intention-to-treat principle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The findings of this trial may provide clinically relevant evidence to support rapid initiation of XR-NTX treatment in patients with OUD and inform clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/en.irct.ir\/trial\/81525<\/jats:ext-link>\n                      , Iranian Registry of Clinical Trials IRCT20250123064499N1.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1933443","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:53:21Z","timestamp":1791352401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of naltrexone-accelerated versus sublingual buprenorphine in opioid withdrawal management and initiating injectable naltrexone treatment: study protocol for a randomized controlled trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Saeede","family":"Jafari","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afarin","family":"Rahimi-Movaghar","sequence":"additional","affiliation":[{"name":"Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Noroozi","sequence":"additional","affiliation":[{"name":"Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooneh","family":"Malekifar","sequence":"additional","affiliation":[{"name":"Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Fotouhi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1550518","article-title":"Global burden on drug use disorders from 1990 to 2021 and projections to 2046","volume":"13","author":"Zongyi","year":"2025","journal-title":"Front Public Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-23283-1","article-title":"Global, regional, and national burden of opioid use disorder from 1990 to 2021: a statistical analysis of incidence, mortality, and disability-adjusted life years","volume":"25","author":"Fang","year":"2025","journal-title":"BMC Public Health"},{"key":"B3","volume-title":"WHO Updates Guidelines on Opioid Dependence Treatment and Overdose Prevention","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajad.12711","article-title":"Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies","volume":"27","author":"Bisaga","year":"2018","journal-title":"Am J Addict"},{"key":"B5","doi-asserted-by":"publisher","first-page":"Cd001333","DOI":"10.1002\/14651858.CD001333.pub4","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","unstructured":"Vivitrol (Naltrexone for Extended-Release Injectable Suspension) Approval Letter\n          \n          2010"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/add.14735","article-title":"Opioid use and dropout from extended\u2010release naltrexone in a controlled trial: implications for mechanism","volume":"115","author":"Nunes","year":"2020","journal-title":"Addiction"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30852-7","article-title":"New directions in the treatment of opioid withdrawal","volume":"395","author":"Srivastava","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-025-00576-9","article-title":"High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study","volume":"20","author":"Mordal","year":"2025","journal-title":"Addict Sci Clin Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.05.033","article-title":"The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review","volume":"119","author":"Dunn","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.08.007","article-title":"Outpatient versus inpatient opioid detoxification: a randomized controlled trial","volume":"40","author":"Day","year":"2011","journal-title":"J Subst Abuse Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"Am J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13024","article-title":"Transition of patients with opioid use disorder from buprenorphine to extended\u2010release naltrexone: a randomized clinical trial assessing two transition regimens","volume":"29","author":"Comer","year":"2020","journal-title":"Am J Addict"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.02.023","article-title":"Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial","volume":"187","author":"Bisaga","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108482","article-title":"Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial","volume":"219","author":"Levin","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"B18","first-page":"46","article-title":"Psychometric properties of severity of dependence scale (SDS) in people with drug and alcohol dependency","volume":"12","author":"Habibi","year":"2018","journal-title":"Q J Res Addict"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/nur.4770130405","article-title":"A critical review of visual analogue scales in the measurement of clinical phenomena","volume":"13","author":"Wewers","year":"1990","journal-title":"Res Nurs Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"key":"B21","article-title":"Comparison of the efficacy of Buprenorphine and Clonidine in detoxification of opioid-dependents","volume":"4","author":"Ziaaddini","year":"2012","journal-title":"Addict Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF quality of life assessment","volume":"28","year":"1998","journal-title":"Psychol Med"},{"key":"B24","article-title":"The World Health Organization quality of Life (WHOQOL-BREF) questionnaire: Translation and validation study of the Iranian version","volume":"4","author":"Nejat","year":"2006","journal-title":"sjsph"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1002\/9780470479216.corpsy0113","article-title":"Beck depression inventory-II","volume-title":"The Corsini Encyclopedia of Psychology, Volume 1","author":"Dozois","year":"2010"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/da.20070","article-title":"Psychometric properties of a Persian\u2010language version of the Beck Depression Inventory\u2010Second edition: BDI\u2010II\u2010PERSIAN","volume":"21","author":"Ghassemzadeh","year":"2005","journal-title":"Depress Anxiety"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0149-7189(79)90094-6","article-title":"Assessment of client\/patient satisfaction: development of a general scale","volume":"2","author":"Larsen","year":"1979","journal-title":"Eval Program Plann"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-012-9516-z","article-title":"Effectiveness of a low-intensity home-based aftercare for patients with severe mental disorders: a 12-month randomized controlled study","volume":"48","author":"Sharifi","year":"2012","journal-title":"Community Ment Health J"},{"key":"B29","article-title":"Clinical safety data management: definitions and standards for expedited reporting E2A","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"1994"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1933443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:53:23Z","timestamp":1791352403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1933443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":29,"alternative-id":["10.3389\/fpsyt.2026.1933443"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1933443","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1933443"}}